[{"orgOrder":0,"company":"Indonesia University","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDONESIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Diquafosol Sodium","moa":"Pyrimidinergic receptor P2Y6 | Pyrimidinergic receptor P2Y4 | Purinergic receptor P2Y1 | Purinergic receptor P2Y2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Indonesia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indonesia University \/ Santen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Indonesia University \/ Santen Pharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals for Diquafosol Sodium

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Indonesia University

                          Country arrow
                          FNCE
                          Not Confirmed

                          Indonesia University

                          Country arrow
                          FNCE
                          Not Confirmed

                          Details : Diquafosol Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dry Eye Syndromes.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 27, 2023

                          Lead Product(s) : Diquafosol Sodium

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Santen Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank